The findings of this study align with prior research that suggests lower effective doses of clozapine are required for patients of Indian descent compared to Western populations. Switching patients of ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

This story also appeared on Everyday Heath's network site BP Hope. The U.S. Food and Drug Administration (FDA) has approved a new sprinkle formulation of valbenazine (Ingrezza) for individuals with ...

Tardive dyskinesia (TD) can be addressed by the right intervention even in severe, refractory cases. These cases, characterized by involuntary muscle movements, are most often caused by antipsychotics ...

Deep brain stimulation (DBS) may be helpful in severe cases of tardive dyskinesia that doesn’t respond to other treatments. Tardive dyskinesia (TD) causes involuntary movements of the tongue, neck, ...

Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...

—That question formed the basis of a new study from the U.K., which sought to learn more about the risk of tardive dyskinesia (TD)—a persistent, potentially irreversible movement disorder—in children ...

After 5 weeks of taking 300 mg of lithium daily, a 76-year-old woman with lurasidone-induced tardive dyskinesia from treatment for Bipolar II Disorder experienced reduced impact, intensity, and ...